JAMES C YAO to Animals
This is a "connection" page, showing publications JAMES C YAO has written about Animals.
Connection Strength
0.169
-
Gastrointestinal neuroendocrine tumors: slow but steady progress. Oncology (Williston Park). 2014 Sep; 28(9):762-3.
Score: 0.021
-
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Clin Cancer Res. 2012 Mar 15; 18(6):1777-89.
Score: 0.018
-
Overcoming antiangiogenic resistance. Clin Cancer Res. 2011 Aug 15; 17(16):5217-9.
Score: 0.017
-
Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer. Drugs. 2011 May 07; 71(7):841-52.
Score: 0.017
-
Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer. 2007 Apr 15; 109(8):1478-86.
Score: 0.012
-
EPA, DHA, and resolvin effects on cancer risk: The underexplored mechanisms. Prostaglandins Other Lipid Mediat. 2024 Oct; 174:106854.
Score: 0.010
-
PPARd dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment. Gastric Cancer. 2023 11; 26(6):904-917.
Score: 0.010
-
Rapid acceleration of KRAS-mutant pancreatic carcinogenesis via remodeling of tumor immune microenvironment by PPARd. Nat Commun. 2022 05 13; 13(1):2665.
Score: 0.009
-
Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors. Int J Mol Sci. 2022 Jan 31; 23(3).
Score: 0.009
-
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021 03; 146:56-73.
Score: 0.008
-
The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy. Cancer Res. 2012 Nov 15; 72(22):5683-91.
Score: 0.005
-
Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res. 2010 Feb 01; 70(3):1111-9.
Score: 0.004
-
Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 2009 Mar 01; 15(5):1821-9.
Score: 0.004
-
Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. Int J Oncol. 2008 Jul; 33(1):161-7.
Score: 0.003
-
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer. 2008 Mar; 15(1):257-66.
Score: 0.003
-
Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer. 2007 Dec 15; 110(12):2682-90.
Score: 0.003
-
The development and characterization of a human midgut carcinoid cell line. Clin Cancer Res. 2007 Aug 15; 13(16):4704-12.
Score: 0.003
-
Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res. 2007 May 15; 67(10):4878-85.
Score: 0.003
-
New drug development in digestive neuroendocrine tumors. Ann Oncol. 2007 Aug; 18(8):1307-13.
Score: 0.003
-
Association of elevated GRP78 expression with increased lymph node metastasis and poor prognosis in patients with gastric cancer. Clin Exp Metastasis. 2006; 23(7-8):401-10.
Score: 0.003
-
Altered expression of transcription factor Sp1 critically impacts the angiogenic phenotype of human gastric cancer. Clin Exp Metastasis. 2005; 22(3):205-13.
Score: 0.003
-
A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis. 2004; 21(8):755-64.
Score: 0.002